<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35839922</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-821X</ISSN><JournalIssue CitedMedium="Internet"><Volume>103</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Archives of physical medicine and rehabilitation</Title><ISOAbbreviation>Arch Phys Med Rehabil</ISOAbbreviation></Journal><ArticleTitle>Prevalence of Neuropsychiatric Disorders in Duchenne and Becker Muscular Dystrophies: A Systematic Review and Meta-analysis.</ArticleTitle><Pagination><StartPage>2444</StartPage><EndPage>2453</EndPage><MedlinePgn>2444-2453</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.apmr.2022.05.015</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0003-9993(22)00472-5</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To estimate the prevalence of neuropsychiatric disorders, including autism spectrum disorders (ASDs), attention-deficit hyperactivity disorder (ADHD), depression, anxiety disorders, and obsessive-compulsive disorder (OCD), in populations with Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD).</AbstractText><AbstractText Label="DATA SOURCES">MEDLINE (via PubMed), Scopus, Web of Science, and Cochrane Library from inception to November 2021.</AbstractText><AbstractText Label="STUDY SELECTION">Observational studies of individuals with DMD or BMD that estimated the prevalence of ASDs, ADHD, depression, anxiety disorders, and OCD in each population.</AbstractText><AbstractText Label="DATA EXTRACTION">A random-effects meta-analysis was performed on each outcome and each population (ie, DMD, BMD).</AbstractText><AbstractText Label="DATA SYNTHESIS">Twenty-three studies were included in the meta-analysis. In DMD, there was a prevalence of 7.0% of ASDs, 18.0% of ADHD, 11.0% of depression, 24.0% of anxiety disorders, and 12.0% of OCD. Furthermore, in BMD, there was a prevalence of 6.0% of ASDs, 28.0% of ADHD, 7.0% of depression, 25.0% of anxiety disorders, and 7.0% of OCD.</AbstractText><AbstractText Label="CONCLUSIONS">The prevalence of these neuropsychiatric disorders is higher among patients with DMD or BMD than among the general population, and the presence of these disorders may negatively influence optimal medical management.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 American Congress of Rehabilitation Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pascual-Morena</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Health and Social Research Center, Universidad de Castilla-La Mancha, Cuenca, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cavero-Redondo</LastName><ForeName>Iv&#xe1;n</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Health and Social Research Center, Universidad de Castilla-La Mancha, Cuenca, Spain; Facultad de Ciencias de la Salud, Universidad Aut&#xf3;noma de Chile, Talca, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reina-Guti&#xe9;rrez</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Health and Social Research Center, Universidad de Castilla-La Mancha, Cuenca, Spain. Electronic address: sara.reina@uclm.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saz-Lara</LastName><ForeName>Alicia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Health and Social Research Center, Universidad de Castilla-La Mancha, Cuenca, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-Gil</LastName><ForeName>Jos&#xe9; Francisco</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Health and Social Research Center, Universidad de Castilla-La Mancha, Cuenca, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez-Vizca&#xed;no</LastName><ForeName>Vicente</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Health and Social Research Center, Universidad de Castilla-La Mancha, Cuenca, Spain; Facultad de Ciencias de la Salud, Universidad Aut&#xf3;noma de Chile, Talca, Chile.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Phys Med Rehabil</MedlineTA><NlmUniqueID>2985158R</NlmUniqueID><ISSNLinking>0003-9993</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020388" MajorTopicYN="Y">Muscular Dystrophy, Duchenne</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="Y">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anxiety disorders</Keyword><Keyword MajorTopicYN="N">Attention deficit disorder with hyperactivity</Keyword><Keyword MajorTopicYN="N">Autism spectrum disorder</Keyword><Keyword MajorTopicYN="N">Depressive disorder</Keyword><Keyword MajorTopicYN="N">Duchenne</Keyword><Keyword MajorTopicYN="N">Muscular dystrophies</Keyword><Keyword MajorTopicYN="N">Muscular dystrophy</Keyword><Keyword MajorTopicYN="N">Neuromuscular diseases</Keyword><Keyword MajorTopicYN="N">Obsessivecompulsive disorder</Keyword><Keyword MajorTopicYN="N">Rehabilitation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>15</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35839922</ArticleId><ArticleId IdType="doi">10.1016/j.apmr.2022.05.015</ArticleId><ArticleId IdType="pii">S0003-9993(22)00472-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>